AbbVie faces looming patent cliff despite still-strong growth.
Context
What happened: AbbVie Inc. ($ABBV) is rated a Hold, with the analyst saying the current valuation already prices in optimistic growth despite a promising pipeline.
Key numbers: Double-digit revenue growth expected near term from Skyrizi, Rinvoq, and neuroscience assets. Patent cliff looms in the early 2030s. ABBV needs 10% annual growth for a decade to justify current prices.
Why it matters: High debt and heavy dividend commitments restrict capital flexibility, which the analyst says warrants close monitoring despite stable current operations.